{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2022"],"condition":["Colorectal cancer"],"disease":["Colorectal Cancer"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/38819"],"location":["China"],"study_start_month":["4"],"repository":["ECRIN MDR"],"study_status":["Not yet recruiting"],"additional_accession":[]},"is_claimable":false,"name":"A prospective, single-arm, single-center clinical study of Sintilizumab+bevacizumab combined with standard chemotherapy in the second-line treatment of metastatic colorectal cancer","description":"Interventions: test group:Sintilizumab combined with bevacizumab\nPrimary outcome(s): Disease-free survival\nStudy Design: Single arm","dates":{"creation":"2022-04-15"},"accession":"38819","cross_references":{"Chinese Clinical Trial Register":["ChiCTR2200058633"]}}